<DOC>
	<DOCNO>NCT02882828</DOCNO>
	<brief_summary>Tools develop unit calculate inter-dose AUC ( Area Under Curve ) immunosuppressive drug ( ISD ) base limited number blood concentration ( i.e. , blood sample ) use Bayesian method . Since 2005 , implement tool expert system make available transplant community successful ISBA ( Immunosuppressive drug Bayesian dose Adjustment ) website . Briefly , first need develop population pharmacokinetic model use rich pharmacokinetic ( PK ) profile ( 10 sample per patient dose interval ) . The model develop use inference ISD PK parameter new patient use Bayesian estimation . Bayes ' theorem base conditional probability : individual PK parameter estimate base know PK parameter population ( mean distribution ) , give dose concentration observe patient . Our previous study show limited sampling strategy ( LSS ) base 3 sample collect within first 3 hour drug intake estimate adequately interdose AUC ISD . In present study , AUC0-24h recommend dose calculate use Bayesian estimator previously develop use PK data clinical trial run Veloxis , propose clinician via dedicate website comparable ISBA .</brief_summary>
	<brief_title>PK Assessment Tacrolimus Exposure Before After Switch From Twice Daily Immediate-release ( Prograf® ) Once-daily Prolonged Release Tacrolimus ( Envarsus® )</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . Adult ( ≥ 18 yearold ) male female patient 2 . Recipient single kidney liver allograft 3 . Patient transplant 2 week less 1 year enrolment 4 . Patient stable Prograf® dose , define follow criterion : Criterion 1 : unchanged Prograf® dose least one week ; , apply criterion # 2 Criterion 2 : unchanged Prograf® dose since last two therapeutic drug monitoring ( TDM ) 5 . Patient decision make switch Prograf® Envarsus® 6 . Written inform consent obtain prior studyrelated procedure 7 . Patient tacrolimus C0 4 12 µg/L V1 8 . Patient hematocrit &gt; 27 % V1 1 . Patient present contraindication tacrolimus accord summary product characteristic ( SmPC ) Envarsus® 2 . Recipient transplant organ kidney liver 3 . Patient treat Prograf® le 7 day enrolment 4 . Patient previously treat investigational agent stop least 7 day prior enrolment 5 . Pregnant lactate woman ( base declaration ) 6 . Patient judicial protection 7 . Patient incapable understanding purpose risk study , give write informed consent , unwilling comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>